Cyclopharm (ASX:CYC) EBIT: A$-17.81 Mil (TTM As of Dec. 2025)

What is Cyclopharm EBIT?

Cyclopharm ASX:CYC 46 EBIT is A$-17.81 Mil as of Dec. 2025. GuruFocus rates ASX:CYC with a GF Score™ of 46/100 and a GF Value™ of A$0.84 (Possible Value Trap). The stock has 7 warning signs investors should review.

Cyclopharm's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was A$-9.97 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-17.81 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Cyclopharm's annualized ROC % for the quarter that ended in Dec. 2025 was -146.70%. Cyclopharm's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -81.85%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Cyclopharm's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -27.76%.

Cyclopharm (ASX:CYC) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Cyclopharm's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

	ROC % (Q: Dec. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2025 )	+	Invested Capital (Q: Dec. 2025 ))	/ count )
=	-52.18 * ( 1 - 4.61% )	/	( (35.991	+	31.868)	/ 2 )
=	-49.774502	/	33.9295
=	-146.70 %

where

	Invested Capital		(Q: Jun. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	55.913	-	7.511	-	( 12.411	-	max(0, 11.363	-	36.267	+	12.411	))
=	35.991

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	46.101	-	7.607	-	( 6.626	-	max(0, 11.262	-	28.461	+	6.626	))
=	31.868

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Cyclopharm's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2025 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2025		Q: Dec. 2025
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-19.93	/	( ( (12.542 + max(13.117, 0))	+	(13.397 + max(9.643, 0)) )	/	2 )
=	-19.93	/	( ( 25.659	+	23.04 )	/	2 )
=	-19.93	/	24.3495
=	-81.85 %

where Working Capital is:

	Working Capital		(Q: Jun. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(8.464	+	14.178	+	1.214)	-	(7.511	+	3.217	+	0.010999999999999)
=	13.117

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(6.975	+	11.435	+	1.934)	-	(7.607	+	0	+	3.094)
=	9.643

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Cyclopharm's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2025 )
	=	-17.808	/	64.147
	=	-27.76 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyclopharm EBIT Related Terms

Cyclopharm EBIT Historical Data

* Premium members only.

The historical data trend for Cyclopharm's EBIT can be seen below:

Cyclopharm EBIT Chart

Cyclopharm Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT

Get a 7-Day Free Trial

-4.33

-5.96

-4.17

-13.04

-17.81

Cyclopharm Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
EBIT	Get a 7-Day Free Trial															-1.62	-7.46	-5.58	-7.84	-9.97

ASX:CYC vs MCK, COR, CAH: EBIT Comparison

For the Medical Distribution subindustry, Cyclopharm's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cyclopharm EV-to-EBIT vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Cyclopharm's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cyclopharm's EV-to-EBIT falls into.

Save Embed

46GF Score

Cyclopharm Ltd ASX:CYC

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Cyclopharm EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-17.81 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of A$-17.81 Mil mean?

Cyclopharm (ASX:CYC) has a EBIT of A$-17.81 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Cyclopharm.

Is Cyclopharm's EBIT too high?

Cyclopharm's current EBIT is A$-17.81 Mil. Overall, Cyclopharm has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Cyclopharm's EBIT compare to MCK and COR?

Cyclopharm's EBIT of A$-17.81 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Medical Distribution company?

A good EBIT depends on the Medical Distribution industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Cyclopharm. Cyclopharm's current EBIT is A$-17.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Cyclopharm stock overvalued right now?

Based on GuruFocus' analysis, Cyclopharm (ASX:CYC) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.84, compared to a current price of A$0.50 — trading 40.5% below its estimated fair value. The current EBIT is A$-17.81 Mil. Cyclopharm's overall GF Score™ is 46/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Cyclopharm (ASX:CYC), the current EBIT is A$-17.81 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cyclopharm (ASX:CYC) Overvalued in 2026?

Based on GuruFocus' analysis, Cyclopharm stock appears to be undervalued. The current stock price of A$0.50 is trading 40.5% below its estimated GF Value™ of A$0.84. GuruFocus considers Cyclopharm to be Possible Value Trap.

Key valuation signals for ASX:CYC:

EBIT: A$-17.81 Mil
GF Value™: A$0.84 vs. price of A$0.50 (40.5% below fair value)
GF Score™: 46/100 with 7 warning signs

No single metric tells the full story. See the ASX:CYC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cyclopharm Business Description

Industry Healthcare Medical Distribution

Comparable Companies ASX:MYX ASX:PGC MCK COR CAH ASX:SIG HSIC SHSE:601607 HKSE:01099 XSWX:GALE SHSE:600332 SHSE:600998 TSE:7459 OSTO:ASKER MIL:AMP SHSE:600511 TSE:2784 SHSE:600739 NZSE:EBO TSE:9987

Address 1 The Crescent, Unit 4, Kingsgrove, Sydney, NSW, AUS, 2208

Website https://cyclopharm.com.au

Cyclopharm Ltd is a health technology company offering solutions related to functional lung ventilation imaging. Its proprietary product Technegas is a broad-spectrum diagnostic lung imaging technology product for the visualisation of pulmonary ventilation and lung function. The company sells its products to healthcare institutions and medical professionals. Maximum revenue is generated from its Technegas products and services, which include the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. Geographically, the company generates maximum revenue from its business in Europe, and the rest from Asia Pacific, Canada, the USA, and other regions.

46GF Score

Get the complete analysis for ASX:CYC

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.50

Price

A$0.84

GF Value

View ASX:CYC Analysis

See EBIT data for all stocks →